Vincent Vultaggio - Oct 4, 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Principal Accounting Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Vincent Vultaggio
Stock symbol
ZNTL
Transactions as of
Oct 4, 2024
Transactions value $
-$5,098
Form type
4
Date filed
10/4/2024, 06:01 PM
Previous filing
Apr 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$5.1K -1.6K -4.52% $3.18 33.9K Oct 4, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 A portion of the shares were sold automatically to satisfy withholding tax obligations upon the vesting of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on September 20, 2023.